In vitro model of neuroinflammation: Efficacy of cannabigerol, a non-psychoactive cannabinoid

International Journal of Molecular Sciences

Volumn 19, Issue 7, 2018, Pages

  Gugliandolo, Agnese ^a   Pollastro, Federica ^b   Grassi, Gianpaolo ^c   Bramanti, Placido ^a   Mazzon, Emanuela ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c Research Centre for Industrial Crops   (Italy)

Author keywords

Cannabigerol; Cannabis sativa; Neuroinflammation; Oxidative stress; Phytocannabinoid

Indexed keywords

3 NITROTYROSINE; CANNABIGEROL; CASPASE 3; COPPER ZINC SUPEROXIDE DISMUTASE; GAMMA INTERFERON; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LIPOPOLYSACCHARIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BAX; PROTEIN BCL 2; TRANSCRIPTION FACTOR NRF2; TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENT; BAX PROTEIN, MOUSE; CANNABINOID; CASP3 PROTEIN, MOUSE; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; IMMUNOCYTOCHEMISTRY; MOUSE; MTT ASSAY; NERVOUS SYSTEM INFLAMMATION; NEURONAL CELL LINE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAW 264.7 CELL LINE; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION REGULATION; MACROPHAGE; METABOLISM; MOTONEURON; SECRETION (PROCESS); TOXICITY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CANNABINOIDS; CASPASE 3; CELLS, CULTURED; CULTURE MEDIA; GENE EXPRESSION REGULATION; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MOTOR NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; RAW 264.7 CELLS;

EID: 85049849050     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms19071992     Document Type: Article

References (38)

1. Morales, P.; Hurst, D.P.; Reggio, P.H. Molecular targets of the phytocannabinoids: A complex picture. Prog. Chem. Org. Nat. Prod. 2017, 103, 103-131. [PubMed]
2. Jackson, S.J.; Diemel, L.T.; Pryce, G.; Baker, D. Cannabinoids and neuroprotection in cns inflammatory disease. J. Neurol. Sci. 2005, 233, 21-25. [CrossRef] [PubMed]
3. Cabral, G.A.; Griffin-Thomas, L. Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocr. Metab. Immune Disord. Drug Targets 2008, 8, 159-172. [CrossRef] [PubMed]
4. Gowran, A.; Noonan, J.; Campbell, V.A. The multiplicity of action of cannabinoids: Implications for treating neurodegeneration. CNS Neurosci. Ther. 2011, 17, 637-644. [CrossRef] [PubMed]
5. Pisanti, S.; Malfitano, A.M.; Ciaglia, E.; Lamberti, A.; Ranieri, R.; Cuomo, G.; Abate, M.; Faggiana, G.; Proto, M.C.; Fiore, D., et al. Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacol. Ther. 2017, 175, 133-150. [CrossRef] [PubMed]
6. Burstein, S. Cannabidiol (cbd) and its analogs: A review of their effects on inflammation. Bioorg. Med. Chem. 2015, 23, 1377-1385. [CrossRef] [PubMed]
7. Giacoppo, S.; Gugliandolo, A.; Trubiani, O.; Pollastro, F.; Grassi, G.; Bramanti, P.; Mazzon, E. Cannabinoid cb2 receptors are involved in the protection of raw264.7 macrophages against the oxidative stress: An in vitro study. Eur. J. Histochem. EJH 2017, 61, 2749. [CrossRef] [PubMed]
8. Borrelli, F.; Fasolino, I.; Romano, B.; Capasso, R.; Maiello, F.; Coppola, D.; Orlando, P.; Battista, G.; Pagano, E.; Di Marzo, V., et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem. Pharmacol. 2013, 85, 1306-1316. [CrossRef] [PubMed]
9. Granja, A.G.; Carrillo-Salinas, F.; Pagani, A.; Gomez-Canas, M.; Negri, R.; Navarrete, C.; Mecha, M.; Mestre, L.; Fiebich, B.L.; Cantarero, I., et al. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. J. Neuroimmune Pharmacol. 2012, 7, 1002-1016. [CrossRef] [PubMed]
10. Carrillo-Salinas, F.J.; Navarrete, C.; Mecha, M.; Feliu, A.; Collado, J.A.; Cantarero, I.; Bellido, M.L.; Munoz, E.; Guaza, C. A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis. PLoS ONE 2014, 9, e94733. [CrossRef] [PubMed]
11. Garcia, C.; Gomez-Canas, M.; Burgaz, S.; Palomares, B.; Gomez-Galvez, Y.; Palomo-Garo, C.; Campo, S.; Ferrer-Hernandez, J.; Pavicic, C.; Navarrete, C., et al. Benefits of vce-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental parkinson’s disease: Possible involvement of different binding sites at the ppargamma receptor. J. Neuroinflamm. 2018, 15, 19. [CrossRef] [PubMed]
12. Valdeolivas, S.; Navarrete, C.; Cantarero, I.; Bellido, M.L.; Munoz, E.; Sagredo, O. Neuroprotective properties of cannabigerol in huntington’s disease: Studies in r6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics 2015, 12, 185-199. [CrossRef] [PubMed]
13. Liu, Z.; Zhou, T.; Ziegler, A.C.; Dimitrion, P.; Zuo, L. Oxidative stress in neurodegenerative diseases: From molecular mechanisms to clinical applications. Oxid. Med. Cell. Longev. 2017, 2017, 2525967. [CrossRef] [PubMed]
14. Chen, W.W.; Zhang, X.; Huang, W.J. Role of neuroinflammation in neurodegenerative diseases (review). Mol. Med. Rep. 2016, 13, 3391-3396. [CrossRef] [PubMed]
15. Leszek, J.; Barreto, G.E.; Gasiorowski, K.; Koutsouraki, E.; Avila-Rodrigues, M.; Aliev, G. Inflammatory mechanisms and oxidative stress as key factors responsible for progression of neurodegeneration: Role of brain innate immune system. CNS Neurol. Disord. Drug Targets 2016, 15, 329-336. [CrossRef] [PubMed]
16. Chitnis, T.; Weiner, H.L. Cns inflammation and neurodegeneration. J. Clin. Investig. 2017, 127, 3577-3587. [CrossRef] [PubMed]
17. Angelova, P.R.; Abramov, A.Y. Role of mitochondrial ros in the brain: From physiology to neurodegeneration. FEBS Lett. 2018, 592, 692-702. [CrossRef] [PubMed]
18. Cobley, J.N.; Fiorello, M.L.; Bailey, D.M. 13 reasons why the brain is susceptible to oxidative stress. Redox Biol. 2018, 15, 490-503. [CrossRef] [PubMed]
19. Biswas, S.K. Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox? Oxid. Med. Cell. Longev. 2016, 2016, 5698931. [CrossRef] [PubMed]
20. Mammana, S.; Fagone, P.; Cavalli, E.; Basile, M.S.; Petralia, M.C.; Nicoletti, F.; Bramanti, P.; Mazzon, E. The role of macrophages in neuroinflammatory and neurodegenerative pathways of alzheimer’s disease, amyotrophic lateral sclerosis, and multiple sclerosis: Pathogenetic cellular effectors and potential therapeutic targets. Int. J. Mol. Sci. 2018, 19, 831. [CrossRef] [PubMed]
21. Diaz-Alonso, J.; Paraiso-Luna, J.; Navarrete, C.; Del Rio, C.; Cantarero, I.; Palomares, B.; Aguareles, J.; Fernandez-Ruiz, J.; Bellido, M.L.; Pollastro, F., et al. Vce-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of huntington’s disease. Sci. Rep. 2016, 6, 29789. [CrossRef] [PubMed]
22. Wang, H.; Xu, Y.S.; Wang, M.L.; Cheng, C.; Bian, R.; Yuan, H.; Wang, Y.; Guo, T.; Zhu, L.L.; Zhou, H. Protective effect of naringin against the lps-induced apoptosis of pc12 cells: Implications for the treatment of neurodegenerative disorders. Int. J. Mol. Med. 2017, 39, 819-830. [CrossRef] [PubMed]
23. Gugliandolo, A.; Giacoppo, S.; Ficicchia, M.; Aliquo, A.; Bramanti, P.; Mazzon, E. Eruca sativa seed extract: A novel natural product able to counteract neuroinflammation. Mol. Med. Rep. 2018, 17, 6235-6244. [CrossRef] [PubMed]
24. Rajan, T.S.; Giacoppo, S.; Trubiani, O.; Diomede, F.; Piattelli, A.; Bramanti, P.; Mazzon, E. Conditioned medium of periodontal ligament mesenchymal stem cells exert anti-inflammatory effects in lipopolysaccharide-activated mouse motoneurons. Exp. Cell Res. 2016, 349, 152-161. [CrossRef] [PubMed]
25. Villapol, S. Roles of peroxisome proliferator-activated receptor gamma on brain and peripheral inflammation. Cell. Mol. Neurobiol. 2018, 38, 121-132. [CrossRef] [PubMed]
26. Liu, Y.; Lu, J.; Shi, J.; Hou, Y.; Zhu, H.; Zhao, S.; Liu, H.; Ding, B.; Yin, Y.; Yi, G. Increased expression of the peroxisome proliferator-activated receptor gamma in the immune system of weaned pigs after escherichia coli lipopolysaccharide injection. Vet. Immunol. Immunopathol. 2008, 124, 82-92. [CrossRef] [PubMed]
27. Liu, Y.L.; Shi, J.X.; Lu, J.; Che, Z.Q.; Zhu, H.L.; Hou, Y.Q.; Yin, Y.L.; Zhao, S.J.; Ding, B.Y.; Liu, H.M. Up-regulated expression of peroxisome proliferator-activated receptor gamma in the hypothalamic-pituitary-adrenal axis of weaned pigs after escherichia coli lipopolysaccharide challenge. Vet. J. 2010, 184, 230-235. [CrossRef] [PubMed]
28. O’Sullivan, S.E. An update on ppar activation by cannabinoids. Br. J. Pharmacol. 2016, 173, 1899-1910. [CrossRef] [PubMed]
29. Naoi, M.; Maruyama, W.; Shamoto-Nagai, M.; Yi, H.; Akao, Y.; Tanaka, M. Oxidative stress in mitochondria: Decision to survival and death of neurons in neurodegenerative disorders. Mol. Neurobiol. 2005, 31, 81-93. [CrossRef]
30. Beal, M.F. Oxidatively modified proteins in aging and disease. Free Radic. Biol. Med. 2002, 32, 797-803. [CrossRef]
31. Forstermann, U.; Sessa, W.C. Nitric oxide synthases: Regulation and function. Eur. Heart J. 2012, 33, 829-837. [CrossRef] [PubMed]
32. Hayes, J.D.; Dinkova-Kostova, A.T. The nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci. 2014, 39, 199-218. [CrossRef] [PubMed]
33. Dinkova-Kostova, A.T.; Kostov, R.V.; Kazantsev, A.G. The role of nrf2 signaling in counteracting neurodegenerative diseases. FEBS J. 2018. [CrossRef] [PubMed]
34. Johnson, D.A.; Johnson, J.A. Nrf2--a therapeutic target for the treatment of neurodegenerative diseases. Free Radic. Biol. Med. 2015, 88, 253-267. [CrossRef] [PubMed]
35. Yamazaki, H.; Tanji, K.; Wakabayashi, K.; Matsuura, S.; Itoh, K. Role of the keap1/nrf2 pathway in neurodegenerative diseases. Pathol. Int. 2015, 65, 210-219. [CrossRef] [PubMed]
36. Kobayashi, E.H.; Suzuki, T.; Funayama, R.; Nagashima, T.; Hayashi, M.; Sekine, H.; Tanaka, N.; Moriguchi, T.; Motohashi, H.; Nakayama, K., et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat. Commun. 2016, 7, 11624. [CrossRef] [PubMed]
37. Quinti, L.; Dayalan Naidu, S.; Trager, U.; Chen, X.; Kegel-Gleason, K.; Lleres, D.; Connolly, C.; Chopra, V.; Low, C.; Moniot, S., et al. Keap1-modifying small molecule reveals muted nrf2 signaling responses in neural stem cells from huntington’s disease patients. Proc. Natl. Acad. Sci. USA 2017, 114, E4676-E4685. [CrossRef] [PubMed]
38. Xagorari, A.; Roussos, C.; Papapetropoulos, A. Inhibition of lps-stimulated pathways in macrophages by the flavonoid luteolin. Br. J. Pharmacol. 2002, 136, 1058-1064. [CrossRef] [PubMed]